Comparison of Itraconazole, Voriconazole, and Posaconazole As Oral Antifungal Prophylaxis in Pediatric Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2013 Nov 1

PMID 24173819

Citations 19

Authors

M Doring

O Blume

S Haufe

U Hartmann

A Kimmig

C-P Schwarze

P Lang

R Handgretinger

I Muller

Affiliations

Soon will be listed here.

Abstract

Oral antifungal prophylaxis with extended-spectra azoles is widely used in pediatric patients after allogeneic hematopoietic stem cell transplantation (HSCT), while controlled studies for oral antifungal prophylaxis after bone marrow transplantation in children are not available. This survey analyzed patients who had received either itraconazole, voriconazole, or posaconazole. We focused on the safety, feasibility, and initial data of efficacy in a cohort of pediatric patients and adolescents after high-dose chemotherapy and HSCT. Fifty consecutive pediatric patients received itraconazole, 50 received voriconazole, and 50 pediatric patients received posaconazole after HSCT as oral antifungal prophylaxis. The observation period lasted from the start of oral prophylactic treatment with itraconazole, voriconazole, or posaconazole until two weeks after terminating the oral antifungal prophylaxis. No incidences of proven or probable invasive mycosis were observed during itraconazole, voriconazole, or posaconazole treatment. A total of five possible invasive fungal infections occurred, two in the itraconazole group (4%) and three in the voriconazole group (6%). The percentage of patients with adverse events potentially related to clinical drugs were 14% in the voriconazole group, 12% in the itraconazole group, and 8% in the posaconazole group. Itraconazole, voriconazole, and posaconazole showed comparable efficacy as antifungal prophylaxis in pediatric patients after allogeneic HSCT.

Citing Articles

Characterization of the Use and Efficacy of Isavuconazonium Sulfate in a Pediatric Oncology and Stem Cell Transplant Population: A Single Institution Retrospective Review.

Kunvarjee B, Siver M, Mathew S, Steiger S, Lee Y, Spitzer B J Pediatr Hematol Oncol. 2024; 46(2):e143-e146.

PMID: 38237014 PMC: 11881917. DOI: 10.1097/MPH.0000000000002812.

A Review of Population Pharmacokinetic Models of Posaconazole.

Ding Q, Huang S, Sun Z, Chen K, Li X, Pei Q Drug Des Devel Ther. 2022; 16:3691-3709.

PMID: 36277600 PMC: 9584355. DOI: 10.2147/DDDT.S384637.

Therapeutic drug monitoring and genotyping guide the application of voriconazole in children.

Chen X, Xiao Y, Li H, Huang Z, Gao J, Zhang X Transl Pediatr. 2022; 11(8):1311-1322.

PMID: 36072540 PMC: 9442201. DOI: 10.21037/tp-22-156.

Antifungal Prophylaxis With Posaconazole in Immunocompromised Children Younger Than 13 Years.

Maquera-Afaray J, Luna-Vilchez M, Salazar-Mesones B, Portillo-Alvarez D, Uribe-Ramirez L, Taipe-Sedano G J Pediatr Pharmacol Ther. 2022; 27(1):57-62.

PMID: 35002560 PMC: 8717622. DOI: 10.5863/1551-6776-27.1.57.

Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Model of () Infection.

Fernandez O, Rosales-Chilama M, Quintero N, Travi B, Wetzel D, Gomez M Antimicrob Agents Chemother. 2021; 66(1):e0142521.

PMID: 34694879 PMC: 8765415. DOI: 10.1128/AAC.01425-21.

References

Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K . Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010; 95(10):1762-8. PMC: 2948103. DOI: 10.3324/haematol.2009.020073. View

Espinel-Ingroff A, Canton E, Gibbs D, Wang A . Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin.... J Clin Microbiol. 2007; 45(3):858-64. PMC: 1829139. DOI: 10.1128/JCM.01900-06. View

Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B . Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol. 2003; 21(24):4615-26. DOI: 10.1200/JCO.2003.04.052. View

Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M . Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004; 21(5):645-53. DOI: 10.1016/j.ejps.2004.01.005. View

Maertens J, Marchetti O, Herbrecht R, Cornely O, Fluckiger U, Frere P . European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2010; 46(5):709-18. DOI: 10.1038/bmt.2010.175. View

Cesaro S, Strugo L, Alaggio R, Cecchetto G, Rigobello L, Pillon M . Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience. Support Care Cancer. 2003; 11(11):722-7. DOI: 10.1007/s00520-003-0523-z. View

Raad I, Graybill J, Bustamante A, Cornely O, Gaona-Flores V, Afif C . Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis. 2006; 42(12):1726-34. DOI: 10.1086/504328. View

Maertens J, Groll A, Cordonnier C, de la Camara R, Roilides E, Marchetti O . Treatment and timing in invasive mould disease. J Antimicrob Chemother. 2010; 66 Suppl 1:i37-43. DOI: 10.1093/jac/dkq440. View

Cornely O, Bohme A, Buchheidt D, Einsele H, Heinz W, Karthaus M . Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica. 2008; 94(1):113-22. PMC: 2625427. DOI: 10.3324/haematol.11665. View

10.

Winston D, Bartoni K, Territo M, Schiller G . Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2010; 17(4):507-15. DOI: 10.1016/j.bbmt.2010.04.017. View

11.

Sanchez-Ortega I, Vazquez L, Montes C, Patino B, Arnan M, Bermudez A . Effect of posaconazole on cyclosporine blood levels and dose adjustment in allogeneic blood and marrow transplant recipients. Antimicrob Agents Chemother. 2012; 56(12):6422-4. PMC: 3497182. DOI: 10.1128/AAC.01489-12. View

12.

Cornely O, Maertens J, Winston D, Perfect J, Ullmann A, Walsh T . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356(4):348-59. DOI: 10.1056/NEJMoa061094. View

13.

Schmalreck A, Willinger B, Haase G, Blum G, Lass-Florl C, Fegeler W . Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study. Mycoses. 2012; 55(3):e124-37. DOI: 10.1111/j.1439-0507.2011.02165.x. View

14.

Morgenstern G, Prentice A, Prentice H, Ropner J, Schey S, Warnock D . A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. Br J Haematol. 1999; 105(4):901-11. DOI: 10.1046/j.1365-2141.1999.01465.x. View

15.

Mann P, McNicholas P, Chau A, Patel R, Mendrick C, Ullmann A . Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009; 53(12):5026-34. PMC: 2786324. DOI: 10.1128/AAC.01031-09. View

16.

Winston D, Maziarz R, Chandrasekar P, Lazarus H, Goldman M, Blumer J . Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003; 138(9):705-13. DOI: 10.7326/0003-4819-138-9-200305060-00006. View

17.

Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347(6):408-15. DOI: 10.1056/NEJMoa020191. View

18.

Ascioglu S, Rex J, De Pauw B, Bennett J, Bille J, Crokaert F . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2001; 34(1):7-14. DOI: 10.1086/323335. View

19.

Cesaro S, Milano G, Aversa F . Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis. 2010; 30(4):595-6. DOI: 10.1007/s10096-010-1123-8. View

20.

Doring M, Muller C, Johann P, Erbacher A, Kimmig A, Schwarze C . Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012; 12:263. PMC: 3514296. DOI: 10.1186/1471-2334-12-263. View